PE20120221A1 - Procedimiento para hacer n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida y materiales de partida para la misma - Google Patents

Procedimiento para hacer n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida y materiales de partida para la misma

Info

Publication number
PE20120221A1
PE20120221A1 PE2011002097A PE2011002097A PE20120221A1 PE 20120221 A1 PE20120221 A1 PE 20120221A1 PE 2011002097 A PE2011002097 A PE 2011002097A PE 2011002097 A PE2011002097 A PE 2011002097A PE 20120221 A1 PE20120221 A1 PE 20120221A1
Authority
PE
Peru
Prior art keywords
methyl
phenyl
indol
procedure
mixture
Prior art date
Application number
PE2011002097A
Other languages
English (en)
Spanish (es)
Inventor
Murat Acemoglu
Joginder S Bajwa
David John Parker
Joel Slade
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38832681&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120221(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20120221A1 publication Critical patent/PE20120221A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE2011002097A 2006-06-12 2007-06-08 Procedimiento para hacer n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida y materiales de partida para la misma PE20120221A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80452706P 2006-06-12 2006-06-12
US86787806P 2006-11-30 2006-11-30

Publications (1)

Publication Number Publication Date
PE20120221A1 true PE20120221A1 (es) 2012-03-21

Family

ID=38832681

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2011002097A PE20120221A1 (es) 2006-06-12 2007-06-08 Procedimiento para hacer n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida y materiales de partida para la misma
PE2007000720A PE20080851A1 (es) 2006-06-12 2007-06-08 Procedimiento para hacer n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida y materiales de partida para la misma

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2007000720A PE20080851A1 (es) 2006-06-12 2007-06-08 Procedimiento para hacer n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida y materiales de partida para la misma

Country Status (31)

Country Link
US (2) US20090306405A1 (OSRAM)
EP (2) EP2394991B1 (OSRAM)
JP (2) JP5431926B2 (OSRAM)
KR (2) KR101493530B1 (OSRAM)
CN (4) CN101466674A (OSRAM)
AR (1) AR061296A1 (OSRAM)
AU (1) AU2007257883B2 (OSRAM)
BR (1) BRPI0712847A2 (OSRAM)
CA (1) CA2653657C (OSRAM)
CL (2) CL2007001691A1 (OSRAM)
DK (1) DK2032533T3 (OSRAM)
EC (1) ECSP088978A (OSRAM)
ES (2) ES2553255T3 (OSRAM)
GT (1) GT200800282A (OSRAM)
HR (1) HRP20130798T1 (OSRAM)
IL (2) IL195211A (OSRAM)
IN (1) IN2015DN00910A (OSRAM)
JO (1) JO2900B1 (OSRAM)
MA (1) MA30513B1 (OSRAM)
MX (2) MX2008015898A (OSRAM)
MY (1) MY147576A (OSRAM)
NO (1) NO341870B1 (OSRAM)
NZ (1) NZ572707A (OSRAM)
PE (2) PE20120221A1 (OSRAM)
PL (1) PL2032533T3 (OSRAM)
PT (1) PT2032533E (OSRAM)
RU (1) RU2448090C2 (OSRAM)
TN (1) TNSN08507A1 (OSRAM)
TW (1) TWI395734B (OSRAM)
WO (1) WO2007146718A2 (OSRAM)
ZA (1) ZA200809490B (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000004075A1 (it) 2020-02-27 2021-08-27 Flamma Spa Processo per la preparazione di panobinostat

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB146260A (en) 1918-07-11 1921-08-11 Elektro Osmose Ag A process for preparing proteids charged with immune substances
GB8531612D0 (en) * 1985-12-23 1986-02-05 Beecham Wuelfing Gmbh & Co Kg Compounds
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
JP2004517334A (ja) 2001-01-09 2004-06-10 ノバルティス アクチエンゲゼルシャフト 化合物のインビボ活性をスクリーニングする迅速な方法
AU2002351844B2 (en) 2001-11-06 2006-12-21 Novartis Ag Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination
MY147013A (en) * 2006-06-12 2012-10-15 Novartis Ag Process for making salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide

Also Published As

Publication number Publication date
EP2032533B1 (en) 2013-04-03
JP5431926B2 (ja) 2014-03-05
NO20090137L (no) 2009-03-03
IL195211A (en) 2014-08-31
JP5809223B2 (ja) 2015-11-10
KR20090015969A (ko) 2009-02-12
CL2010000973A1 (es) 2011-07-01
JO2900B1 (en) 2015-09-15
EP2394991A1 (en) 2011-12-14
AU2007257883B2 (en) 2011-09-29
TNSN08507A1 (en) 2010-04-14
IL233836A (en) 2017-05-29
MY147576A (en) 2012-12-31
BRPI0712847A2 (pt) 2012-08-07
NO341870B1 (no) 2018-02-12
JP2009540008A (ja) 2009-11-19
JP2014058532A (ja) 2014-04-03
CN101466674A (zh) 2009-06-24
EP2032533A2 (en) 2009-03-11
US8536346B2 (en) 2013-09-17
US20090306405A1 (en) 2009-12-10
NZ572707A (en) 2011-12-22
CA2653657C (en) 2015-10-27
ECSP088978A (es) 2009-01-30
KR101493530B1 (ko) 2015-02-13
IL233836A0 (en) 2014-09-30
PL2032533T3 (pl) 2013-08-30
MX366213B (es) 2019-07-01
CN103086944A (zh) 2013-05-08
CA2653657A1 (en) 2007-12-21
AU2007257883A1 (en) 2007-12-21
PT2032533E (pt) 2013-06-28
EP2032533B8 (en) 2013-12-11
RU2448090C2 (ru) 2012-04-20
MA30513B1 (fr) 2009-06-01
EP2394991B1 (en) 2015-09-23
IN2015DN00910A (OSRAM) 2015-07-10
TWI395734B (zh) 2013-05-11
ZA200809490B (en) 2009-10-28
CL2007001691A1 (es) 2008-05-16
CN102174008A (zh) 2011-09-07
GT200800282A (es) 2009-03-09
HRP20130798T1 (en) 2013-09-30
US20120010418A1 (en) 2012-01-12
AR061296A1 (es) 2008-08-20
MX2008015898A (es) 2009-01-12
WO2007146718A2 (en) 2007-12-21
KR20140117703A (ko) 2014-10-07
WO2007146718A3 (en) 2008-06-19
KR101540194B1 (ko) 2015-07-28
CN102167678B (zh) 2013-08-28
ES2553255T3 (es) 2015-12-07
TW200815345A (en) 2008-04-01
HK1162029A1 (en) 2012-08-17
HK1126759A1 (en) 2009-09-11
RU2008151726A (ru) 2010-07-20
CN102167678A (zh) 2011-08-31
PE20080851A1 (es) 2008-08-18
DK2032533T3 (da) 2013-07-01
ES2416286T3 (es) 2013-07-31
IL195211A0 (en) 2009-08-03

Similar Documents

Publication Publication Date Title
BRPI0500585B8 (pt) processo para a síntese de ivabradina e sais de adição desta com um ácido farmaceuticamente aceitável
BRPI0608732A2 (pt) composto ou um sal, hidrato, solvato, complexo ou pró-droga farmaceuticamente aceitável do mesmo, sal de um composto, processo para a preparação de um composto, uso de um composto, composição farmacêutica, e, produto
JO3138B1 (ar) املاح n- هيدروكسي -3- [4-[[[2-(2-مثيل-h1-اندول -3-يل)ايثيل]امينو]مثيل]فنيل]-e2-2-بروبيناميد
ES2655091T3 (es) Derivados del ácido pirrolidíncarboxílico como agonistas del receptor 43 acoplado a proteína G (GPR43), composición farmacéutica y métodos para su uso en el tratamiento de trastornos metabólicos
MY149337A (en) Polymorphs of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
BRPI0500480A (pt) processo para a sìntese de (1s)-4,5-dimetóxi- 1-(metilaminometil)-benzociclobutano e sais de adição deste, e aplicação na sìntese de ivabradina e sais de adição desta com um ácido farmaceuticamente aceitável
EA200602066A1 (ru) Кристаллические полиморфные формы n-[8(2-гидроксибензоил)амино]каприлата натрия
JO3099B1 (ar) طريقة تصنيع املاح من n- هيدروكسي -3- [4-[[[2-(2-مثيل-h 1-اندول -3-يل)ايثيل]امينو]مثيل]فنيل]-e-2-2بروبان اميد
PE20040907A1 (es) Derivados de anilinopirazol
PE20120221A1 (es) Procedimiento para hacer n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida y materiales de partida para la misma
RU2011114991A (ru) Производное аминокислоты
UA95289C2 (en) Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
UA97243C2 (en) Crystalline anhydrous form of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
AR063692A1 (es) Procedimiento de preparacion de compuestos antagonistas de cgrp(peptido relacionado con el gen de la calcitonina)
AR037878A1 (es) Procedimientos para preparar inhibidores de tipo-1 de intercambiador sodio-hidrogeno
CY1117493T1 (el) Αλατα του ν-υδροξυ-3-[4-[[[2-(2-μεθυλ-1η-ινδολ-3-υλ)αιθυλ]αμινο]μεθυλο]φαινυλο]-2ε-2-προπεναμιδιου
TH105399B (th) อนุพันธ์ออกซาไดแอโซลและการใช้สารเหล่านี้เป็นเมทาโบโทรปิกกลูตาเมท รีเซพเตอร์ โพเทนชิเอเตอร์-842
AR055006A1 (es) Sales farmaceuticamente utiles de derivados de acido carboxilico

Legal Events

Date Code Title Description
FG Grant, registration